The China pharmaceutical intermediate market is set for significant expansion, with a projected valuation of USD 9,309.7 million in 2025, growing at a CAGR of 6.4% to reach USD 17,276.3 million by 2035. The country’s stronghold in cost-effective manufacturing and scalability continues to attract global pharmaceutical companies seeking to optimize production costs. The rising demand …